GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Cash Payments

Transgene (XPAR:TNG) Cash Payments


View and export this data going back to 1998. Start your Free Trial

What is Transgene Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


Transgene (XPAR:TNG) Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.